Solutions for the industry
Large scale antibody production
We have the expertise and capacity to produce both custom monoclonal and polyclonal antibodies in large volume. We are able to handle large demanding projects with remarkable flexibility to meet the customer’s requirements and SOP's.
25 years+ Expertise in antibody development and production
For over 25 years, Eurogentec has been recognized as a trusted manufacturer of custom antibodies dedicated to diagnostic, biotech and pharma partners worldwide.
We develop antibodies with high flexibility and a strong focus on customer service. A team of project managers directly handles the requests and adapts our processes and strategies to best meet our sponsors’ needs. Some processes may be subject to an evaluation by the ethical committee for approval.
Trusted quality
Delivering high-quality products is fundamental for us.
Our comprehensive Quality Management System ensures that our customers receive the product they need.
Belgian facilities
Located in Belgium, our State-of-the-art facilities enable us to produce from small to very large batches of monoclonal or polyclonal antibodies.
Our facilities are equipped with advanced technologies for antibody production, operated by experienced scientists.
Animal welfare
The facilities comply with the highest standards for animal welfare, including FELASA, GLP, GMP, BELAC, UK Home Office Animals Scientific Procedures Act.
GMP
Antibodies fragments can be produced in our GMP biomanufacturing facilities, accredited by Belgian Health Authorities. They are equipped with 4 GMP Fermentation suites (from 80 L to 2200 L fermenters).
Polyclonal antibody production
We adapt the production to the customer’s project size. We produce and deliver serum from small to large volume, or up to multiple grams of purified antibodies .
According to the project, we can handle regularly several liters of serum from rabbits or goats.
Our immunization programs can also be conducted over a long period of time.
Large scale monoclonal antibody production
Producing monoclonal antibodies in vitro from hybridoma is an efficient and reproducible process. Depending on the request, we can generate up to 100 g high quality mAbs using adapted production scheme, or our proprietary technology to boost the cells production yields.
We can manage projects from the generation of hybridomas and molecular engineering of mAbs up to dedicated QC and characterization, purification, and formatting.